CURASIGHT A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.1 DKK | -8.82% |
|
-9.45% | -48.73% |
| 04-16 | Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients | CI |
| 04-12 | Curasight A/S Announces Board Changes | CI |
| Sales 2024 * | - | Sales 2025 * | 43M 6.17M 493M | Capitalization | 181M 25.96M 2.08B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | 35M 5.02M 402M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.21 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 4 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -8.82% | ||
| 1 week | -9.45% | ||
| Current month | -16.51% | ||
| 1 month | -15.35% | ||
| 3 months | -52.85% | ||
| 6 months | -53.09% | ||
| Current year | -48.73% |
1 week
9.00
10.55
1 month
9.0011.35
Current year
8.1619.90
1 year
8.1629.00
3 years
8.1633.60
5 years
8.1644.05
10 years
8.1644.05
| Managers | Title | Age | Since |
|---|---|---|---|
Carsten Nielsen
FOU | Founder | 41 | 31/12/12 |
Jacob Madsen
FOU | Founder | 52 | 31/12/12 |
Andreas Kjaer
FOU | Founder | 61 | 31/12/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kirsten Drejer
BRD | Director/Board Member | 68 | 03/05/21 |
Per Falholt
CHM | Chairman | 65 | 31/12/19 |
| Chief Executive Officer | 57 | 31/12/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 9.1 | -8.82% | 5,234 |
| 25/04/24 | 9.98 | +0.20% | 890 |
| 24/04/24 | 9.96 | -1.39% | 6,953 |
| 23/04/24 | 10.1 | +0.50% | 4,633 |
| 22/04/24 | 10.05 | 0.00% | 13,286 |
End-of-day quote NORDIC GROWTH MARKET, April 25, 2024
More quotes
Curasight A/S is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). The technology provides improved diagnosis and risk stratification in multiple cancer types.
Calendar
22/05/2024
- Q1 2024 Earnings Release
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -48.73% | 25.92M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CURAS Stock
